表紙
市場調査レポート

野兎病:パイプライン製品の分析

Tularaemia - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 293888
出版日 ページ情報 英文 80 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。
Back to Top
野兎病:パイプライン製品の分析 Tularaemia - Pipeline Review, H1 2016
出版日: 2016年05月31日 ページ情報: 英文 80 Pages
概要

野兎病(ツラレミア)は、野兎病菌(Francisella tularensis)と呼ばれる細菌に起因する感染症です。主に節足動物(特にダニや蚊)に咬まれることで感染します。皮膚、結膜嚢、口腔咽頭粘膜を介して、感染した動物や動物性物質との直接接触、汚染された食品や水の摂取、汚染されたほこりやエアロゾルの吸入によって感染します。症状は、皮膚潰瘍、リンパ腺の腫れや痛み、発熱、悪寒などです。治療には、抗生物質や健康的な生活スタイルが推奨されています。

当レポートでは、野兎病に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

野兎病の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

調査中の治療薬:大学/研究機関別

パイプライン製品の概要

  • 治験段階の製品
  • 初期段階の製品

開発中の製品:企業別

調査中の製品:大学/研究機関別

治療薬の開発に従事している企業

  • Aradigm Corporation
  • Arno Therapeutics, Inc.
  • DynPort Vaccine Company LLC
  • Emergent BioSolutions Inc.
  • EpiVax, Inc.
  • Grifols, S.A.
  • Merck & Co., Inc.
  • Tetraphase Pharmaceuticals Inc.

治療薬の評価

  • 単独療法の場合
  • 標的別
  • 作用機序別
  • 投与法別
  • 分子タイプ別

薬剤のプロファイル

パイプライン製品の最新動向

休止状態のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 最新ニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8128IDB

Summary

Global Markets Direct's, 'Tularaemia - Pipeline Review, H1 2016', provides an overview of the Tularaemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Tularaemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Tularaemia and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Tularaemia
  • The report reviews pipeline therapeutics for Tularaemia by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Tularaemia therapeutics and enlists all their major and minor projects
  • The report assesses Tularaemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Tularaemia

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Tularaemia
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Tularaemia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Tularaemia Overview
  • Therapeutics Development
    • Pipeline Products for Tularaemia - Overview
    • Pipeline Products for Tularaemia - Comparative Analysis
  • Tularaemia - Therapeutics under Development by Companies
  • Tularaemia - Therapeutics under Investigation by Universities/Institutes
  • Tularaemia - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Tularaemia - Products under Development by Companies
  • Tularaemia - Products under Investigation by Universities/Institutes
  • Tularaemia - Companies Involved in Therapeutics Development
    • Aradigm Corporation
    • Arno Therapeutics, Inc.
    • DynPort Vaccine Company LLC
    • Emergent BioSolutions Inc.
    • EpiVax, Inc.
    • Grifols, S.A.
    • Merck & Co., Inc.
    • Tetraphase Pharmaceuticals Inc.
  • Tularaemia - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AR-12 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ARD-3100 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ARD-3150 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ciprofloxacin hydrochloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • EV-035 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit Enoyl-Reductase for Anthrax and Tularaemia - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit InhA for Infectious Diseases - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • solithromycin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SRI-011225 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TP-271 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tularaemia [strain A] vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tularaemia [strain B] vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tularaemia vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tularemia vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Tularaemia - Recent Pipeline Updates
  • Tularaemia - Dormant Projects
  • Tularaemia - Discontinued Products
  • Tularaemia - Product Development Milestones
    • Featured News & Press Releases
      • Sep 14, 2015: AR-12 Abstracts Accepted for Podium Presentation and Three Posters at ICAAC/ICC Annual Meeting 2015
      • May 14, 2015: Arno Therapeutics Announces Preclinical Data Demonstrating Broad-Spectrum Antiviral Activity for AR-12
      • Apr 30, 2015: Arno Therapeutics Receives European Orphan Drug Designation for AR-12 to Treat Two Infectious Diseases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Tularaemia, H1 2016
  • Number of Products under Development for Tularaemia - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Tularaemia - Pipeline by Aradigm Corporation, H1 2016
  • Tularaemia - Pipeline by Arno Therapeutics, Inc., H1 2016
  • Tularaemia - Pipeline by DynPort Vaccine Company LLC, H1 2016
  • Tularaemia - Pipeline by Emergent BioSolutions Inc., H1 2016
  • Tularaemia - Pipeline by EpiVax, Inc., H1 2016
  • Tularaemia - Pipeline by Grifols, S.A., H1 2016
  • Tularaemia - Pipeline by Merck & Co., Inc., H1 2016
  • Tularaemia - Pipeline by Tetraphase Pharmaceuticals Inc., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Tularaemia Therapeutics - Recent Pipeline Updates, H1 2016
  • Tularaemia - Dormant Projects, H1 2016
  • Tularaemia - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Tularaemia, H1 2016
  • Number of Products under Development for Tularaemia - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top